PamGene announces results of its IOpener®-NSCLC test to predict response to immune checkpoint inhibition in patients with advanced non-small cell lung cancer at the 2022 ESMO Immuno-Oncology meeting in Geneva, Switzerland

‘s-Hertogenbosch, the Netherlands, December 1, 2022

PamGene International B.V., an in-vitro diagnostics and biomarker services company developing blood-based immunotherapy guidance tests, will present the results of its IOpener®-NSCLC test on December 8. The test aimed to predict the likelihood for response to immune checkpoint inhibition in patients with advanced non-small cell lung cancer. The results will be presented at the 2022 European Society for Medical Oncology (ESMO) annual Immuno-Oncology meeting in Geneva, Switzerland.

In July 2022, PamGene announced the successful CE-IVD registration of the IOpener®-NSCLC device. At this year’s annual ESMO Immune-Oncology meeting, which will be held at Palexpo exhibition center in Geneva on December 7-9, researchers from the Erasmus MC Cancer Institute Rotterdam, University Medical Center Nijmegen, Elisabeth Tweesteden Hospital Tilburg, Diakonessenhuis Utrecht, Isala Hospital Zwolle, Amphia Hospital Breda, Catharina Hospital Eindhoven, Amsterdam Medical Center (VUmc), Oncode Institute and University Medical Center Leiden, will present in a prospective and blinded validation study that tyrosine kinase activity profiling in blood predicts the response to immune checkpoint inhibition for patients with advanced NSCLC.

Presentation:

Title: The IOpener study: tyrosine kinase activity profiling to predict response to immune checkpoint inhibitors in patients with advanced stage non-small cell lung cancer

Speaker: Karlijn de Joode (Rotterdam, Netherlands)

Date: Thursday, December 8, 2022; Poster number: 31P

About IOpener® – A liquid biopsy immunotherapy guidance test
The IOpener® is a blood-based diagnostic test that supports immunotherapy guidance. The test measures the kinase activity in peripheral blood mononuclear cells isolated from a single tube of blood from a patient to determine the likelihood of responding to immunotherapy. The test is based on ample experience with the technology for measuring and interpreting kinase activity to support academic and clinical research. The IOpener®-NSCLC is a CE-IVD registered device that is developed and manufactured in PamGene’s ISO 13485:2016 certified facility.

About PamGene

PamGene International B.V. has recently intensified its efforts to develop and commercialize a blood-based immunotherapy guidance test, the IOpener®, to improve patient outcomes. The company’s kinase-activity profiling technology and proprietary software algorithms support clinicians in their treatment decisions using the IOpener® assay. PamGene’s robust and unique peptide microarray technology for multiplex kinase-activity profiling is also used to provide dedicated assay services for patient stratification for clinical trials, biomarker discovery, and gaining mechanistic insights needed to understand human diseases. PamGene is headquartered in ‘s-Hertogenbosch, the Netherlands.

For more information, please contact Rinie van Beuningen, Vice President Business Development – iopener@pamgnene.com  – +31 (0) 73 615 80 80 – www.pamgene.com.

IOpener® is a registered trademark in the U.S. and European Union community

Related Posts